FundLens
81
Pharma & HealthcareStrong Buy

HDFC Pharma And Healthcare

HDFC · Direct–Growth · rank #2 of 19 by Smart Score

Data updated

Trailing returns

vs Nifty 500 (index-fund proxy)
1 Year
27.3%
+29.4% vs index
3 Years
5 Years
Since launch
32.3%

Year-by-year performance

last entry = YTD
2024
+52.2%
2025
+2.4%
2026
+28.8%

Why this score

HDFC Pharma And Healthcare scores 81/100 — #2 of 19 Pharma & Healthcare fund (Strong Buy). It stands out for sharpe ratio and alpha — beating 97% of peers on sharpe ratio. It has no major weak spot vs the category.

Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.

Sharpe ratio1.84 · 97th percentile in category
Alpha21.88 · 97th percentile in category
Sortino ratio2.64 · 97th percentile in category
1Y return27.29% · 97th percentile in category
Fund size3310.64 Cr · 71st percentile in category
Volatility14.02 · 66th percentile in category

Top holdings

top 5 = 30.7% of portfolio
1.Divi's Laboratories Ltd9.54%
2.Sun Pharmaceutical Industries Ltd8.94%
3.Torrent Pharmaceuticals Ltd4.08%
4.Max Healthcare Institute Ltd4.06%
5.Lupin Ltd4.04%

39 disclosed equity positions · portfolio as of Aug 2026 · weights are % of total corpus.

Other Pharma & Healthcare funds